Pluri

Company Overview

Snapshot

Founded in January 2003, Pluri operates with 201–500 employees and has raised a total of $136.9M across 13 funding rounds from 4 investors. The company was publicly listed on NASDAQ in April 2003, marking a significant milestone in its journey.

Business overview

Pluri develops cell-based products for commercial applications, focusing on global well-being and sustainability. The company leverages a patented 3D cell expansion system to create novel cell-based solutions across various initiatives, including regenerative medicine, food technology, and climate change. Its technology is designed for accurate, scalable, cost-effective, and consistent mass cell production, serving industries that require efficient cell manufacturing.

Strategic signal

In October 2025, Pluri's subsidiary Coffeesai announced a strategic collaboration with Instituto del Café de Chiapas to advance cell-based coffee manufacturing in Mexico. This partnership signals Pluri's continued expansion into the food technology sector and its commitment to leveraging its 3D cell-based technology for sustainable agricultural solutions, indicating a potential for significant market disruption in the food industry.

Company Intelligence Q&A

What was Pluri's financial performance in the full year 2023?

Pluri reported a US$0.77 loss per share for the full year 2023, an improvement compared to a US$1.28 loss in FY 2022.

What strategic collaboration did Pluri's subsidiary Coffeesai announce in October 2025?

In October 2025, Pluri's subsidiary Coffeesai announced a strategic collaboration with Instituto del Café de Chiapas to advance cell-based coffee manufacturing in Mexico.

What new immunotherapy platform did Pluri launch in May 2024?

In May 2024, Pluri launched a novel immunotherapy platform for solid tumor cancer treatment, focusing on unleashing the power of MAIT cells.

What partnership did Pluri form with BrainStorm Cell Therapeutics in November 2024?

In November 2024, Pluri partnered with BrainStorm Cell Therapeutics to support the manufacturing for the NurOwn® Phase 3b trial, a cellular therapy for neurodegenerative diseases.

What was the outcome of Pluri's collaboration with Bar-Ilan University in October 2024?

In October 2024, Pluri collaborated with Bar-Ilan University to advance cancer immunotherapy for solid tumors, a project supported by the Israel Innovation Authority.